Michael Oneka
Family Medicine · Muskegon, MINPI 1366457129
Payments from drug & device makers
Across 296 payments — averaging $29.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$1K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$1K
- Viiv Healthcare Company$1K
- Vanda Pharmaceuticals Inc.$718
- AstraZeneca$558
- AbbVie$540
- plus $3K from 31 others
What the payments were for
- Food & beverage$8,747100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Gilead | 22 | $1,440 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 30 | $1,212 |
| Viiv Healthcare Company | 31 | $1,209 |
| Vanda Pharmaceuticals Inc. | 18 | $718 |
| AstraZeneca | 11 | $558 |
| AbbVie(2 entities) | 20 | $540 |
| Otsuka America Pharmaceutical, Inc. | 18 | $464 |
| Novo Nordisk | 23 | $439 |
| Pfizer | 27 | $302 |
| Lilly USA, LLC | 12 | $257 |
| Bayer | 5 | $233 |
| Sunovion Pharmaceuticals Inc. | 19 | $222 |
| Axsome Therapeutics, Inc. | 2 | $139 |
| Supernus Pharmaceuticals, Inc. | 11 | $131 |
| Amgen | 8 | $122 |
| LEO Pharma Inc. | 1 | $107 |
| Novartis | 5 | $82 |
| Johnson & Johnson(2 entities) | 4 | $79 |
| Merck | 4 | $58 |
| Grifols USA, LLC | 2 | $46 |
| GSK | 3 | $43 |
| Alkermes, Inc. | 2 | $40 |
| Astellas Pharma US Inc | 2 | $40 |
| Teva Pharmaceuticals USA, Inc. | 3 | $37 |
| SK Life Science, Inc. | 1 | $28 |
| Sanofi Pasteur Inc. | 1 | $23 |
| Ironshore Pharmaceuticals Inc. | 1 | $22 |
| Sumitomo Pharma America, Inc. | 1 | $18 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $18 |
| Smith+Nephew | 1 | $17 |
| Exact Sciences | 1 | $17 |
| Phathom Pharmaceuticals, Inc. | 1 | $17 |
| Neurelis, Inc. | 1 | $14 |
| Shield Therapeutics Inc | 1 | $14 |
| Mylan Specialty L.p. | 1 | $14 |
| E.r. Squibb & Sons, L.L.C. | 1 | $14 |
| Boehringer Ingelheim | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$8,747 in reported general payments places this provider in the 95th percentile of 3,945 family medicine providers in Michigan.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 298 | $360,475 |
| TrulicityDulaglutide | 124 | $136,112 |
| JanuviaSitagliptin Phosphate | 91 | $114,938 |
| FarxigaDapagliflozin Propanediol | 57 | $70,834 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 87 | $70,565 |
| VraylarCariprazine Hcl | 26 | $51,847 |
| EliquisApixaban | 42 | $45,685 |
| XareltoRivaroxaban | 27 | $38,743 |
| OzempicSemaglutide | 19 | $37,787 |
| SymbicortBudesonide/Formoterol Fumarate | 44 | $15,756 |
| TradjentaLinagliptin | 14 | $12,698 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 279 | $9,792 |
| Breo ElliptaFluticasone/Vilanterol | 23 | $9,010 |
| MyrbetriqMirabegron | 13 | $8,422 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 13 | $7,681 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Tradjenta, Combivent Respimat | $13 | $378,236323 claims |
| Lilly USA, LLCTrulicity | $257 | $136,112124 claims |
| MerckJanuvia | $58 | $114,93891 claims |
| AstraZenecaFarxiga, Symbicort | $558 | $86,590101 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $43 | $79,575110 claims |
| AbbVieVraylar | $540 | $51,84726 claims |
| PfizerEliquis | $302 | $45,68542 claims |
| Johnson & JohnsonXarelto | $79 | $38,74327 claims |
| Novo NordiskOzempic | $439 | $37,78719 claims |
| Astellas Pharma US IncMyrbetriq | $40 | $8,42213 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,945 family medicine providers in Michigan.
Other family medicine in Muskegon
- Derrick WilliamsonSouthfield$9.9M
- Rebecca RivardRoseville$7M
- Paul BensonBerkley$4.2M
- Michael HafranEast Lansing$2.7M
- Mitzie HewittBuckley$1.3M
- Loren ChudlerSouthfield$1.3M
- Solomon AmsterWhite Lake$981K
- Matt RosenbergJackson$559K
- Rhonda MejeurGrand Rapids$493K
- Steve LasaterSaint Johns$291K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.